TrialNature communications2026

Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial.

Li-Ting Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.